Medtronic (MDT)
NYSEHealth CareMedical DevicesSnapshot 2026-07-08
$83.84+0.94%
Close 2026-07-07 · 1-day change
Reading MDT? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track MDT free→NYSEHealth CareMedical DevicesSnapshot 2026-07-08
Reading MDT? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track MDT free→QuarterlyIQ Insights · MDT
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Results of Operations and Financial Condition On June 03, 2026, Medtronic plc, a public limited company organized under the laws of Ireland, issued a press release announcing its full year and fourth quarter and fiscal year 2026 financial results. A copy of the Medtronic financial results press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Executive Vice President and President, Neuroscience Portfolio — Brett Wall: Brett Wall is departing from his position and will be replaced by Dr. Kweli Thompson.
Regulation FD Disclosure On April 24, 2026, Medtronic plc (“Medtronic” or the “Company”) announced that an unauthorized third party had accessed data in certain of the Company’s information technology (“IT”) systems. Upon identifying the unauthorized access, the Company promptly took steps to contain the incident, activated its incident response protocols, and engaged leading external cybersecurity experts to support its investigation and remediation efforts. Based on its investigation to dat…
Regulation FD Disclosure On March 18, 2026, MiniMed Group, Inc. (MiniMed), a consolidated subsidiary of Medtronic plc (Company) announced that the U.S. Food and Drug Administration (FDA) has cleared the MiniMed Flex™, a next-generation discreet, smartphone-controlled insulin pump. The clearance of the MiniMed Flex by the FDA was several months earlier than anticipated, and will facilitate the earlier commercialization of this key MiniMed product. The research and development of the MiniMed Fl…
Results of Operations and Financial Condition On February 17, 2026, Medtronic plc, a public limited company organized under the laws of Ireland, issued a press release announcing its third quarter fiscal year 2026 financial results. A copy of the press release is furnished as Exhibit 99.1 to this report.
Results of Operations and Financial Condition On November 18, 2025, Medtronic plc, a public limited company organized under the laws of Ireland, issued a press release announcing its second quarter fiscal year 2026 financial results. A copy of the press release is furnished as Exhibit 99.1 to this report.
Executive Vice President, Enterprise Operations — Gregory L. Smith: Gregory L. Smith is retiring from the company and will join a private equity-held organization.
Entry into a Material Definitive Agreement. Notes Offering On September 29, 2025, Medtronic, Inc., an indirect wholly owned subsidiary of Medtronic public limited company (“Medtronic plc”), issued €750,000,000 aggregate principal amount of its 2.950% Senior Notes due 2030 (the “2030 Notes”) and €750,000,000 aggregate principal amount of its 4.200% Senior Notes due 2045 (the “2045 Notes” and together with the 2030 Notes, the “Notes”), in an underwritten offering (the “Offering”) pursuant to a…
Other Events. On September 29, 2025 (the “Redemption Date”), Medtronic Luxco redeemed all €500,000,000 of its outstanding 2.625% Senior Notes due 2025 (CUSIP Number: 58507L AX7) (the “Redemption Notes”). The Redemption Notes were redeemed at a redemption price equal to 100% of the principal amount, plus accrued and unpaid interest to, but not including, the Redemption Date. Medtronic Luxco’s obligation to redeem the Redemption Notes was conditioned upon the completion of the issuance and sale…
Other Events. Underwriting Agreement On September 15, 2025, Medtronic, Inc., Medtronic plc and Medtronic Luxco entered into an underwriting agreement (the “Underwriting Agreement”) with the underwriters listed therein, for which Deutsche Bank AG, London Branch and Goldman Sachs & Co. LLC acted as representatives. Pursuant to the Underwriting Agreement, Medtronic, Inc., an indirect wholly owned subsidiary of Medtronic plc, will issue and sell €750,000,000 aggregate principal amount of its 2.95…
Regulation FD Disclosure. On September 15, 2025, Medtronic public limited company (“Medtronic plc”) issued a press release announcing the pricing of the Offering (as defined below), the net proceeds of which are expected to be used to repay Medtronic Global Holdings S.C.A.’s (“Medtronic Luxco”) 0.000% Senior Notes due 2025 and Medtronic Luxco’s 2.625% Senior Notes due 2025. The financial impact from the Offering and the expected use of proceeds was reflected in Medtronic plc’s fiscal year 202…
Results of Operations and Financial Condition On August 19, 2025, Medtronic plc, a public limited company organized under the laws of Ireland, issued a press release announcing its first quarter fiscal year 2026 financial results. A copy of the press release is furnished as Exhibit 99.1 to this report.
Director — John Groetelaars, William Jellison: The Board of Directors increased its size and appointed two new directors.
Director — Dr. Joon Lee: Dr. Joon Lee was appointed as a new director of the company.
EVP and President, Cardiovascular Portfolio — Sean Salmon: Mr. Salmon is departing from his position and will be replaced by Skip Kiil.
Results of Operations and Financial Condition On May 21, 2025, Medtronic plc, a public limited company organized under the laws of Ireland, issued a press release announcing its full year and fourth quarter fiscal year 2025 financial results. A copy of the Medtronic financial results press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Global Controller and Principal Accounting Officer — Jennifer M. Kirk: Ms. Kirk resigned to become the CEO of another company.
Results of Operations and Financial Condition On February 18, 2025 , Medtronic plc, a public limited company organized under the laws of Ireland, issued a press release announcing its third quarter fiscal year 2025 financial results. A copy of the press release is furnished as Exhibit 99.1 to this report.
Chief Financial Officer (CFO) — Thierry Pieton: Appointment of Thierry Pieton as Chief Financial Officer (CFO) with significant compensation and equity incentives.
Results of Operations and Financial Condition On November 19, 2024, Medtronic plc, a public limited company organized under the laws of Ireland, issued a press release announcing its second quarter fiscal year 2025 financial results. A copy of the press release is furnished as Exhibit 99.1 to this report.
Results of Operations and Financial Condition On August 20, 2024, Medtronic plc, a public limited company organized under the laws of Ireland, issued a press release announcing its first quarter fiscal year 2025 financial results. A copy of the press release is furnished as Exhibit 99.1 to this report.
interim Chief Financial Officer — Gary Corona: Gary Corona was appointed as the interim Chief Financial Officer with a compensatory arrangement.
Chief Financial Officer — Karen L. Parkhill: Karen L. Parkhill resigned as Chief Financial Officer, and Gary Corona was appointed as interim CFO.
Executive Vice President and President, Global Regions — Rob ten Hoedt: Rob ten Hoedt retired from the company.
Entry into a Material Definitive Agreement. Notes Offering On June 3, 2024, Medtronic, Inc., an indirect wholly owned subsidiary of Medtronic public limited company (“Medtronic plc”), issued €850,000,000 aggregate principal amount of its 3.650% Senior Notes due 2029 (the “2029 Notes”), €850,000,000 aggregate principal amount of its 3.875% Senior Notes due 2036 (the “2036 Notes”), €600,000,000 aggregate principal amount of its 4.150% Senior Notes due 2043 (the “2043 Notes”), and €700,000,000 a…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.